The abstract is read at the publisher; the summary is JClub's.
High baseline neutrophil-to-lymphocyte ratio (NLR) in YL201-treated patients is linked to inferior treatment response and progression-free survival, especially in NSCLC.
- Why it matters: Inflammation markers could help predict who benefits from B7H3 ADC therapy and who is more likely to experience treatment-related adverse events.
- What they did: In a global phase 1/1b trial, baseline and on-treatment blood counts were used to compute NLR, with Cox and logistic regression testing associations with PFS, response, and TRAEs. Plasma Olink proteomics on 72 samples from 54 patients explored IL-6 links to NLR status.
- The result: High baseline NLR is associated with higher risk of any-grade thrombocytopenia and grade ≥3 TRAEs, and with reduced risk of any-grade asthenia, nausea, and constipation, while IL-6 level may correlate with NLR and clinical benefit probability.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.